Program
ataciguat
Also written as “ataciguat (HMR1766)” and “Ataciguat”.
Its studies are mostly in Aortic Valve Stenosis · Intermittent Claudication · Pain, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 20 open or running | phase 2since Mar 2, 2007 | Mar 2, 2007 | none ahead |
| Kardigan | 11 open or running | phase 3since May 13, 2025 | May 13, 2025 | Aug 31, 2028phase 3 · NCT07001800 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 2, 2007First study: phase 2 study in Intermittent ClaudicationNew to SanofiSanofi · NCT00443287 · 553 enrolled · United States, Austria, Canada and more
- Nov 27, 2008Phase 2 study in PainSanofi · NCT00799656 · 62 enrolled · Austria, Czech Republic, Romania
- May 13, 2025Kardigan's first study: phase 3 study in Aortic Valve StenosisNew to KardiganKardigan · NCT07001800 · 1,276 planned · United States, Canada
Ahead
- Aug 31, 2028Primary completion: phase 3 study in Aortic Valve StenosisKardigan · NCT07001800
TargetBeta
“Soluble guanylate cyclase activator”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Nitroglycerinrule | mediquest-therapeutics | phase 4 | 14 |
| praliciguatrule | Ironwood Pharmaceuticals | phase 2 | 8 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07001800Aortic Valve Stenosis · United States, Canada | 3 | Recruiting | Kardigan | Aug 31, 2028 | 1,276 |
| NCT00799656Pain · Austria, Czech Republic, Romania | 2 | Completed | Sanofi | Jun 2009 | 62 |
| NCT00443287Intermittent Claudication · United States, Austria, Canada and more | 2 | Completed | Sanofi | Oct 2008 | 553 |
How it is read
Names in the registry
- “ataciguat (HMR1766)”, 2 entries
- “Ataciguat”, 1 entry
Conditions, from the studies’ own filings
- Aortic Valve Stenosis, 1 study
- Intermittent Claudication, 1 study
- Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.